**Laser Lithography to Generate Antigens for Autologous Cancer Vaccination**

Jeremy Stubbs MD<sup>1</sup>

<sup>1</sup>Independent Researcher, United States of America

<jeremyb.stubbs@gmail.com>

**Keywords**

Immunotherapy, Antibody, Granulocytes, Eosinophils, Neutrophils, NK cells, T-cells, Crispr

**Introduction**  
Cancer immunotherapy has revolutionized oncology, yet challenges remain in the development of effective, personalized vaccines. This proposal explores the use of lithography technology to generate tumor cell fragments from pathology slices. Lithography is the use of collimated light i.e. lasers with a photomask to etch a pattern on a substrate. Chemically optimized and purified fragments would be injected with adjuvants. The photomask grid pattern dictates fragment size whose optimal dimensions can be determined empirically. Precise molecular disruption exposes native tumor antigens that retain all post-translational modifications unlike another leading cancer vaccine approach – mRNA. Furthermore, if feasible the strategy would be cheap and scalable. Existing technology allows for UV, X-ray, and possibly IR systems to be evaluated.

**Background and Rationale**

In situ vaccination following radiation therapy represents a promising therapeutic strategy that has demonstrated encouraging clinical outcomes. \[5\] However, this is a highly variable process. It’s not clear that radiation produces consistent sized tumor-associated antigen (TAA) fragments. In addition, the highly inflammatory state post-radiation which includes neutrophils who release digestive enzymes may compromise the chemical integrity of fragments, limiting the precision of the immune response

Past attempts for antigen preparation for autologous cancer vaccines have generally relied on enzymatic digestion or mechanical disruption (sonication) of biopsy samples. This is also relatively crude for its lack of ability to make precise sized fragments that maintain the native form of macromolecules.

A slight improvement is a strategy called “Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST).” They used x-rays to kill and fragment tumor cells from a biopsy \[2\] This was not an inspiration for me; I found it after I started writing my proposal. But, it is worth mentioning that it kind of uses the same ingredients: light to fragment tissue for a vaccine, only I think the frequency should be UV and it should use a photomask.

My novel thought was to use UV lithography. UV lithography is the use of a UV laser with a photomask (something that selectively blocks light) to etch patterns on a substrate. It is widely used in the semiconductor industry. The same principles can be applied to fragment tumor-associated antigens in a controlled manner, ensuring the generation of appropriately sized glycopeptides that antigen presenting cells (APC) can process and present on major histocompatibility complexes (MHC).

Compared to the aforementioned techniques, it may offer greater control over antigen integrity, size and immunogenicity. The main differences between this new approach and in situ vaccination following radiation therapy are location of light exposure (inside vs outside the patient) and frequency of light (UV vs Ionizing radiation). The possible advantages are: greater control over antigen size, the option to filter unwanted material, the option to chemically optimize the fragments (optimize immunogenicity, optimize stability of fragments), and the ability to better avoid inflammatory degradation either by chemical optimization (adducts, liposomes, hydrogels) or ex-vivo priming of antigen presenting cells (APCs).

UV laser lithography is widely used in semiconductor fabrication to achieve nanoscale precision (currently the smallest transistor is 2nm which is much smaller than a 20-30 nm ribosome). The reason I think it can be applied to vaccine preparation is because ultraviolet frequency is extremely well suited for breaking organic C-C and C-N bonds. In fact, “laser capture microdissection” is a known method of using UV lasers to dissect individual cells. Because of the nice cuts they make, fluorine-based excimer lasers that operate in the UV-C range (around 193 nm) are also used in eye surgery. Deep UV (200–300 nm) can interact with proteins and DNA without massive heat buildup, making it ideal for precise cellular fragmentation. Femtosecond (fs) or picosecond (ps) pulsed UV lasers are especially good at breaking bonds and not disrupting surrounding tissue.

X-rays are another excellent frequency candidate. In fact, x ray photomasks exist, and lithography systems can achieve nearly the same precision as those that employ UV light. X-rays have significantly more energy than UV light. The cell membrane is approximately 10nm thick. Approximately 20-40% of known tumor-associated antigens (TAA) are membrane bound so it is safe to use the outermost portion as the initial target. As a safety margin, let’s examine the penetration of UV and X rays of 10 nm of tightly wound keratin. By some estimates, the UV (300–350 nm) transmission is ~30–40%, and X-ray (1-10 keV) transmission 99%. Less x-rays will be absorbed, but they are higher energy and break bonds much more effectively when they are absorbed.

X rays have fewer numbers of interactions, but each interaction is more likely to break a chemical bond. The overall efficacy of these frequencies may compensate for the difficulties in their optical manipulation.

You don’t need a $200 million ASML machine to do this. All you need is a reliable UV laser source (a few hundred thousand dollars) and a good UV photomask (a few hundred thousand dollars). Wavelengths and Actual Laser System:

- 266 nm (Deep UV, Nd:YAG 4th harmonic) → High precision, strong protein interactions.
- 213 nm (Even deeper UV, Nd:YAG 5th harmonic) → More precise fragmentation control.
- Excimer Lasers (XeCl at 308 nm, ArF at 193 nm) → Used in eye surgery, could be adapted for tumor antigen fragmentation.

IR frequency light interacts with water much more than UV. Thus it will produce more heat and scattering. Water strongly absorbs IR radiation because its molecular vibrations (stretching and bending of O-H bonds) match the energy of IR photons. A skin cell is approximately 30 um in diameter, which corresponds to 109,000 water molecules lined up end to end. Near-IR (800 nm+) would get absorbed by tissue water before reaching the target. Nevertheless, femtosecond (fs) or picosecond (ps) pulsed IR lasers further might allow intracellular disruption of organic bonds before heating. Pulsed IR lasers are tuned to a wavelength in the ~1300–1500 nm range may also minimize heating but maximize bond breaking. Alternatively, low-energy pulses could cause nanobubble formation or localized pressure bursts, rather than full vaporization.

**Practical Considerations:**

The natural target for a lithography system is a thin layer of material. Pathology slices fit that description perfectly. In order to generate enough material for a vaccine, a sizeable biopsy must be taken which can be cut into hundreds or thousands of slices which are treated with the UV laser. The process of preparation, photomask placement, exposure and post-processing must be streamlined. The slice may need to be cut all the way through or simply scored and broken apart later by mechanical means like sonication.

Immediately after the UV laser (or X ray) you’ll have a burst of reactive molecular species—free radicals, aldehydes, oxidized lipids, broken protein domains, exposed cysteines, etc. These fragments could rapidly rebind, aggregate, or denature, which could: mask antigenic sites, reduce immune visibility, make the “vaccine” messy or less effective. In the short-term, these must be stabilized either chemically or physically by freezing them. In the long-term these need to be chemically stabilized so that they can be given in a vaccine.

If you cut the slices while they are kept at cryogenic temperatures, the bonds may break and not reform until the temperature rises. When you raise the temperature, it will be in the presence of a solution that contains the reagents to chemically neutralize the fragments or lock them into a matrix.

I don’t know enough about organic chemistry to offer a solution for quenching reactive fragments, but the questions you must ask are: Is there any chemical reaction you could use to cap biological molecules, specifically lipids, proteins and large carbohydrates so that they don’t recombine after you cut them with a UV laser? To chemically quench or stabilize the fragments right as they form, before they start cross-linking or misfolding, a buffer solution must be present that contains chemicals that react with the fragments. Options are listed below for a “fragmentation buffer”. While there isn't a single universal "magic bullet" reaction, several chemical strategies could potentially be employed to cap the cut ends of lipids, proteins, and large carbohydrates after UV laser cleavage. The specific reaction and capping agent would need to be carefully chosen based on the type of biomolecule, the likely reactive species generated by the laser, and the desired outcome. For all three types of molecules, having a high concentration of a fast-reacting and specific capping agent present immediately after the laser pulse would be critical for success. Radical scavenging and reactions with newly exposed functional groups (thiols, amines, aldehydes/ketones, reducing ends) appear to be the most promising approaches. To chemically quench or stabilize the fragments right as they form, before they start cross-linking or misfolding, a buffer solution must be present that contains chemicals that react with the fragments. Options are listed below in Table 2. for a “fragmentation buffer”.

Locking them into a matrix for long-term stability might be as easy as thawing them in the presence of a biologically compatible superglue (cyanoacrylate). Maybe sonicate it during the curing process to mechanically distribute the fragments evenly throughout the resulting cyanoacrylate matrix.

Again, I am not a chemist, but I’ll speculate on long-term quenching of fragments. UV laser ablation, especially at 193–248 nm, generates free radicals, carbocations, carbonyls and other oxidized groups, and unstable double bonds. These reactive fragments can recombine, oxidize further, or crosslink, unless they are stabilized quickly. So you want fast-reacting capping agents present in the buffer during irradiation or during thawing.

1\. Proteins – Capping Free Amines, Thiols, and Radicals  
After UV exposure, proteins can be left with:  
Free amines (from lysine or N-termini)  
Free thiols (from cysteine)  
Radicals or oxidized residues (e.g., carbonyls on side chains)

Capping Strategies:  
Iodoacetamide or N-ethylmaleimide (NEM): alkylate thiols to prevent disulfide formation.  
Formaldehyde + sodium cyanoborohydride: for amine capping via reductive methylation.  
Acrylamide: can react with amines and thiols.  
Spin traps (e.g., DMPO, PBN): stabilize free radicals.  
Methionine or other scavengers: quench ROS.

2\. Lipids – Capping Reactive Double Bonds and Aldehydes  
Lipids can form:  
Peroxides and aldehydes (especially polyunsaturated fatty acids)  
Radicals or epoxides

Capping Strategies:  
Butylated hydroxytoluene (BHT) or Trolox: antioxidant scavengers for radicals.  
Hydroxylamine derivatives: react with aldehydes and ketones to form oximes.  
Silylation reagents (e.g., TMS derivatives): protect hydroxyls and carboxylic acids.  
Maleimide-functionalized PEGs: can cap thiol-containing headgroups.

3\. Carbohydrates – Capping Reducing Ends and Hydroxyls  
UV fragmentation of polysaccharides may expose:  
Reducing ends (aldehydes)  
Radicals on carbon chains  
Free hydroxyls

Capping Strategies:  
Sodium borohydride (NaBH4) or cyanoborohydride: reduces aldehydes to stable alcohols.  
Aniline derivatives or hydrazides: form Schiff bases or hydrazones with reducing ends.  
Acetylation or methylation: cap hydroxyls.

One advantage of this strategy is the option to enrich the sample – remove unwanted parts so that you are left with more cancer cells which give a more targeted immune response. You can remove both cellular and non-cellular parts.

Removing non-cancerous cells might be useful, maybe with targeted excision with the UV optical system itself operating like a solid beam not a grid.

A pre-treatment with collagenase might be helpful.  
• Collagen in the stroma can scatter or absorb UV laser energy (collagen’s peptide bonds absorb at ~200–280 nm, overlapping with UV wavelengths like 248 nm). Degrading it first could make ablation more efficient, ensuring the laser focuses on tumor cells and membranes.  
• With ~15–25% of the slice being collagen, pretreatment could dissolve most of it into peptides, leaving a leaner matrix (mostly cells) for the laser to cut. This might yield a higher proportion of phospholipid-rich fragments post-ablation.

Another advantage of this strategy is the option to chemically modify the debris for optimal immunogenicity and stability. You could chemically link the fragments to an immune stimulant. This is different from the stability chemistry mentioned above.

Another option for chemical stability and biological compatibility is to incorporate the fragments into liposomes. There is precedent for this, see “Tumor Cell Membrane‐Based Vaccines: A Potential Boost for Cancer Immunotherapy.” It is research (also out of China) about creating autologous cancer vaccines with liposomes. They used sonication to break up the cells which they then combined with cholesterol or whatever to make hybrid liposomes that contained TAAs. \[4\]

Neutrophils (and other myeloid cells) can indeed respond rapidly to foreign material by releasing reactive oxygen species, proteases, and other enzymes, which could degrade carefully prepared antigen fragments before they reach antigen-presenting cells (APCs) in a meaningful way. This "bystander destruction" is a known issue in vaccine design, especially with tumor lysate-based vaccines.

Here are three viable strategies to improve the vaccine's efficacy:

1\. Ex Vivo Pulsing of APCs (like dendritic cells):

Pros: Highly controlled, allows precise loading of tumor antigens onto MHC molecules.

Cons: Labor-intensive, expensive, and usually autologous (patient-specific).

Potential Optimization: You could combine this with maturation signals (e.g., LPS, CD40L, poly I:C) to enhance APC activation before reinfusion.

2\. Liposome or Nanoparticle Encapsulation:

Pros: Protects antigens from extracellular degradation, improves delivery to lymph nodes, and can be decorated with targeting ligands (e.g., mannose for dendritic cells).

Cons: Requires formulation work and quality control, but very scalable and compatible with off-the-shelf approaches.

Pro Tip: Co-encapsulate immune adjuvants (e.g., CpG, MPLA) with your antigens to boost the immune response.

As a matter of fact, incorporation of cell membranes of tumor cells into nanoparticles and liposomes has been widely tried as cancer vaccines. \[4\] To the best of my knowledge (and the AI’s) no one has used lithography systems to generate those fragments.

3\. Hydrogel or Acrylate Matrix-Based Slow Release:

Pros: Sustained antigen presentation mimics a persistent infection, allowing better immune training.

Cons: Slightly more invasive depending on the delivery route.

Optional Twist: Use enzymatically responsive hydrogels that degrade in response to MMPs or neutrophil elastase, slowly releasing antigen in inflamed tissue.

**Simplified Workflow Concept (with Pre-Irradiation Buffering):**

1. Tumor Tissue or Cell Lysate Preparation: Tumor cells are harvested from the patient as intact tissue sections.
    - A biopsy or resected tumor sample is obtained from the patient.
    - Tissue sections are cut into slices like for a pathology slide approximately 1-2 cells thick to increase the likelihood of success. Likely hundreds or thousands of slices need to be cut.
2. UV Laser Exposure in a Grid Pattern:
    - A UV laser (e.g., excimer or femtosecond laser) or X ray laser with a photomask is used to create precise antigen fragments by exposing the sample to a predetermined grid pattern.
    - The pathology slice could be cut while frozen or thawed. Like the size of the fragments, this must be determined empirically along with when to introduce the fragmentation buffer.
    - Note that the laser can be used to cut the sample several times. In fact, it could cut the pathology slice, which is then turned into a lysate and cut again.
3. Fragmentation Buffer: added before irradiation and contains chemical reagents to prevent recombination.
4. Optional: Thawing and Gentle Sonication to fragment the cut/scored cells.
5. Optional: Form liposomes through known methods like Azafari method. The buffer solution contains components necessary for liposome formation (triacyl glycerides).
6. Optional: Collect and optionally filter or centrifuge to isolate desired particle size range.
7. Optional: chemical modification of fragments

• Use biotin-NHS, PEG-mannose-NHS, or Fc-tagged PEGs during the soak.

• As proteins break apart, their free lysines and N-termini get tagged—simultaneously quenching and targeting the fragments for immunogenicity.  
• Lock the fragments into an acrylate matrix with adjuvant.

1. Reinject fragments with adjuvants or pulse autologous dendritic cells (DCs) ex vivo, which are then reintroduced into the patient. If the fragments are locked into an acrylate matrix, then the entire matrix can be implanted. Or it can be fragmented again, and the composite particles injected with the adjuvant.
2. Immune Activation:  
    • The processed antigens are presented to T cells, initiating an immune response against tumor-specific epitopes.  
    • Co-administered **adjuvants** enhance dendritic cell activation and antigen presentation. A TLR agonist (like CpG DNA, poly-IC, or MPLA) would boost innate immune activation, drawing in antigen-presenting cells. GM-CSF could be injected locally to recruit dendritic cells, ensuring efficient antigen pickup.  
    • A **checkpoint inhibitor** (like anti-PD-1 or anti-CTLA-4) could be combined for even stronger T cell activation.

**Discussion – Part I – Justification and Checkpoint Inhibitors**

This approach leverages lithography technology (lasers + photomask) for precise antigen fragmentation, enabling the development of an autologous cancer vaccine. I think this is a sufficiently unique idea that is just plausible enough to warrant trying.

It is similar to _in situ_ vaccination after radiation therapy, something that has shown promising results in early studies. The main differences are the location of light exposure (inside vs outside the patient) and the frequency of light (UV vs Ionizing radiation). Compared to in situ vaccination following radiation therapy the possible advantages are: greater control over antigen size, the option to filter unwanted material, the option to chemically optimize the fragments (optimize immunogenicity, optimize stability of fragments), and the ability to better avoid inflammatory degradation either by chemical optimization (adducts, liposomes, hydrogels) or ex-vivo priming of antigen presenting cells (APCs).

Like all experimental cancer vaccine strategies, this could be combined with a checkpoint inhibitor (like anti-PD-1 or anti-CTLA-4).

**Discussion – Part II: Scientific Basis of mRNA Cancer Vaccines**

This vaccine strategy could easily complement a treatment plan involving mRNA vaccines, but a head-to-head comparison is warranted. The fundamental distinction between UV lithography-based vaccines and mRNA vaccines lies in antigen heterogeneity versus dose precision. That said, these approaches are not mutually exclusive—they could synergize when used together.

Assumptions Behind mRNA Cancer Vaccines

mRNA cancer vaccines are predicated on the following biological assumptions:

1. Neoantigen Prediction: Mutations in tumor DNA give rise to novel peptides (8–11 amino acids) that may be presented on MHC I.
2. Synthetic Mimicry: These neoantigens can be encoded by mRNA and expressed at the vaccination site, where they are processed and presented similarly.

This leads to two fundamental questions:

- How accurately can we predict which DNA mutations will lead to peptides that are actually presented on MHC I at the tumor site?
- How reliably does mRNA vaccination replicate that same antigen presentation on MHC I at the vaccination site?

In summary, while significant unknowns persist—such as whether two patients with the same HLA genotype but different lysosomal processing genes present the same peptides—mRNA vaccines remain scientifically plausible, justifying their continued exploration in oncology.

Part of my motivation for writing the section is because there is exactly no published criticism of the scientific basis for using mRNA technology for cancer vaccination. I present several logically valid criticisms of the mRNA technology which should be in the general discussion. It may be a promising technology, but it needs to be evaluated with scientific integrity, not sycophant fanboying. There are no papers that evaluate DNA to MHC predictive abilities outside of clinical response. So far the clinical trials have hinged on cherry picked outcomes like progression free survival after complete resection, which depends on a lot of stuff including surgeon performance. The gold standard has always been and will always be overall survival. Data specifically focusing on separate site recurrence vs local recurrence within 5 cm of the excised tumor or in an upstream lymph node is essential to determine adequate study design. I do have a lingering discomfort though because protein subunit vaccines work for plenty of infectious disease. The papers that compare mRNA to peptide vaccines in the context of cancer (like the clinical trials) focus on endpoints other than overall survival in small samples (like 6 rodents). It would be horrible if mRNA technology worked in phase 3 studies then fell short in phase 4 studies, which is why strict scientific standards should be placed on these sorts of studies. Hopefully, future study designs will address these gaps.

I. DNA Sequencing Reliability and Mutation Reproducibility

Modern DNA sequencing (e.g., WGS/WES) is reliable, with >95% sensitivity and >99% specificity for high-confidence mutations when sample quality and sequencing depth are sufficient.

- Databases like COSMIC and TCGA catalogue millions of mutations. COSMIC, for example, includes ~25 million mutations across 1.5 million samples.
- Some driver mutations (e.g., _BRAF V600E_, _KRAS G12D_) are conserved across patients. However, passenger mutations are highly variable, meaning that each patient's mutational landscape is typically unique.

II. Predicting Antigen Presentation

The multi-step process from DNA mutation to MHC I peptide presentation includes:

- Translation
- Proteasomal cleavage
- TAP transport
- MHC binding

Each step introduces variability:

| Step | Prediction Accuracy |
| --- | --- |
| MHC Binding (NetMHCpan) | 80–90% (common HLAs) |
| Proteasomal Cleavage | 70–80% |
| TAP Transport | 60–70% |
| Overall Pipeline | ~50–70% precision, ~60–80% sensitivity for top candidates |

While sufficient for early clinical applications, this remains a highly probabilistic pipeline. Mass spectrometry-based peptidomics is helping refine these predictions, but:

Key criticism: Current databases (e.g., NetMHCpan) rely heavily on mass spec and elution data, rather than the gold standard—T-cell activation assays. Ideally, database entries should be validated using functional assays where in vitro–generated T cells are used to confirm that predicted MHC-peptide complexes elicit a response. To date, no large-scale confirmatory study appears to exist.

One possible reason for this is that neoantigen prediction is embedded in broader pipelines—where outcomes like clinical efficacy are the focus, not mechanistic accuracy. This may limit transparency and slow foundational validation.

III. Dual Presentation: Tumor vs Vaccination Site

In mRNA vaccines, antigen presentation occurs in two places:

1. Vaccination site: mRNA is taken up by APCs (especially DCs), translated, and the encoded peptides are presented on MHC I.
2. Tumor site: Tumor cells present neoantigens derived from mutated DNA.

Overlap is non-trivial, due to:

- Variability in cleavage patterns between tumor cells and DCs
- Differences in peptide processing environments
- Immune evasion at the tumor site

Despite these hurdles, techniques like minimal epitope design and optimized mRNA sequences improve the odds of overlap, justifying continued development.

**Discussion – Part III: Comparative Immunologic Analysis**

Both UV-fragment-based and mRNA vaccines aim to elicit robust CD8+ and CD4+ T cell responses, ultimately enabling immune surveillance of the tumor. The key difference lies in their design philosophy:

mRNA Vaccines: Trust artificial intelligence and curated databases to guide the immune system toward specific tumor targets with consistent, high-dose antigen delivery.

UV Fragmentation Vaccines: Trust the body’s antigen-processing machinery to recognize targets naturally from a broad, heterogeneous antigen pool, albeit at lower dose per epitope and with less batch-to-batch consistency.

Key Comparative Points

| Factor | UV Fragment Vaccine | mRNA Vaccine |
| --- | --- | --- |
| Antigen Breadth | Broad (includes lipids, glycopeptides, PTMs) | Narrow, selected peptides |
| Antigen Dose | Low per epitope | High, focused |
| Reproducibility | Variable across doses | Highly consistent |
| Tumor Heterogeneity Coverage | Higher | Lower, mitigated via multiplexing |
| Cost | Potentially much lower | Expensive (personalized synthesis) |
| Scalability | High (especially globally) | Lower due to cost, IP constraints |
| CD8+ T cell activation | Relies on APC cross-presentation | Direct and indirect (endogenous and exogenous pathways) |
| B cell/MHC II Activation | Likely superior due to natural PTMs | More limited unless specifically engineered |

Detailed Immunologic Differences

CD8+ T Cells require MHC I presentation of peptides (8–11 aa), which occurs via:

- Endogenous pathway (self-antigens processed in cytosol)
- Cross-presentation by APCs (external antigens internalized and routed to MHC I)

mRNA vaccines leverage both routes by encoding optimized sequences for enhanced MHC I binding.

CD4+ T Cells and B Cells, by contrast, interact with MHC II, which presents longer peptides (up to ~25 aa), including glycopeptides and modified proteins. These antigens are processed in lysosomes, a step that likely preserves PTMs better in UV-generated fragments than in engineered mRNA products.

Natural presentation may better reflect tumor antigens in their true biological context, potentially aiding B cell activation, antibody generation, and T helper function.

Final Perspective: Integration, Not Opposition

Both platforms face similar fundamental challenges: immune tolerance to self-antigens, tumor MHC I downregulation, and antigenic drift. Yet each has complementary strengths.

- mRNA vaccines offer targeted, potent stimulation and are advancing rapidly with AI integration.
- UV-fragment-based vaccines provide unmatched antigen diversity, are likely cheaper, and could be more scalable, particularly in low-resource settings.

Ultimately, combining both strategies—e.g., priming with mRNA, boosting with UV-derived fragments—could provide superior breadth, depth, and durability of immune response.

**Discussion – Part IV: Feasibility of UV Lithography-Based Cancer Vaccines**

Is this Strategy Technically Possible?

Two key questions define the feasibility of this approach:

1. Can UV lithography reliably fragment tumor material into immunologically relevant pieces without causing excessive degradation or denaturation?
2. Can these fragments be stabilized long enough for processing, storage, and injection—while still retaining native structure or post-translational modifications (PTMs)?

If both challenges can be addressed, it is highly likely that such a vaccine would induce an immune response.

Although this specific strategy has never been implemented, we can infer feasibility by examining two adjacent technologies:

1\. UV Laser-Based Cellular Dissection (Laser Capture Microdissection, LCM)

What does this tell us about generating small biological fragments using UV light?

LCM is a well-established method for isolating specific cells or microscopic regions of tissue using laser pulses. In pathology, it enables precise anatomical excision—often isolating individual cells, nuclei, or tissue domains—without significant disruption to neighboring regions.

However, LCM is primarily a macroscopic technique for tissue anatomy, not a biochemical tool for controlled protein fragmentation. Still, the underlying technologies—particularly excimer and femtosecond UV lasers—are widely used in material science and semiconductor industries for their ability to break covalent bonds with high spatial precision.

Inference: While LCM itself doesn't address biochemical fragmentation, UV laser systems clearly offer the mechanical precision and energy control necessary to break down biological material in a spatially resolved manner. The challenge will be tuning parameters (wavelength, pulse duration, energy density) to induce fragmentation without widespread denaturation, which would destroy key epitopes.

Importantly, we likely do not need to fragment all the way down to 8–15 amino acid peptides, which are the sizes presented on MHC I. After phagocytosis, antigen-presenting cells (APCs) will naturally process larger fragments in endolysosomes. The goal is to create “bite-sized” antigen chunks that retain structure and post-translational features for natural immune processing—not to generate final peptide epitopes _ex vivo_.

2\. Autologous Cancer Vaccines via Enzymatic or Hypertonic Cell Lysis

What can we learn from these existing cancer lysate vaccines?

Autologous lysate-based vaccines, produced by enzymatic digestion, hypertonic shock, or detergent lysis, have been trialed for decades. These methods typically yield highly heterogeneous mixtures of cellular material.

- Drawback #1: The antigen composition is difficult to characterize precisely. In complex lysates, mass spectrometry struggles to resolve and quantify relevant peptides due to signal overlap and limited dynamic range.
- Drawback #2: These methods often result in protein denaturation, aggregation, and PTM loss, which are crucial for immune recognition, especially for B cells and MHC II-restricted CD4+ T cells.

Inference: Harsh lysis is unpredictable and poorly controlled. UV-mediated fragmentation, if optimized, may provide a more consistent and reproducible method of breaking cells apart while preserving antigenic fidelity—particularly if fragmentation is performed in frozen sections with buffering to limit free radical damage.

Feasibility Bottleneck: UV Penetration and Scattering

A central unknown is how UV light will behave in this application, particularly:

- Scattering and absorption in biological tissue
- Penetration depth through multiple membrane and cytoplasmic layers
- Heat diffusion and its impact on protein structure

UV light in the 200–300 nm range (e.g., excimer lasers at 248 nm or 193 nm) has extremely shallow penetration in biological material due to strong absorption by aromatic amino acids and nucleotides. While this limits bulk tissue access, it may actually be beneficial in this context.

Strategic Advantage: Shallow penetration allows layer-by-layer fragmentation, particularly in thin cryosections. With proper stage control and scanning, this may enable the generation of depth-resolved antigen profiles and reduce the risk of overexposure or widespread protein denaturation.

This raises a broader engineering consideration: rather than treating whole tumors in situ, the most viable approach is likely ex vivo laser treatment of thin tumor slices, either from fresh or frozen samples, under carefully buffered and cooled conditions.

Conclusion: Conditional Feasibility

This approach is technically plausible, but success hinges on optimizing three interdependent factors:

1. Fragmentation Energy Control: UV exposure must be sufficient to disrupt cellular and protein structure without erasing key antigenic features.
2. Spatial Resolution and Penetration: Thin sections and staged exposure may allow fragmentation at subcellular scales with minimal scattering.
3. Post-Processing Stability: The use of a fragmentation buffer—containing radical quenchers, PTM stabilizers, or cryoprotectants—may be essential for preserving immunogenicity and enabling downstream formulation (e.g., in liposomes or hydrogels).

If these can be achieved, UV lithography–based antigen generation may offer a new and highly adaptable platform for autologous cancer vaccination, with unique advantages in antigen diversity, manufacturing cost, and global scalability.

**Future Directions and Initial Experimental Concepts**

This concept deserves benchtop investigation, as it opens the door to a number of promising and unexplored possibilities. Several experimental variables stand out as particularly important to test in the early phases of development:

- Optical parameters – wavelength, exposure time, and laser scanning patterns (e.g., single grid, intersecting grids, multiple passes)
- Sample state – processing tissue slices while frozen vs. thawed
- Mechanical enhancement – applying light sonication after UV exposure to further break apart partially scored cells
- Buffer chemistry – composition of the fragmentation medium and any immediate stabilization agents
- Downstream preservation – exploring chemical capping agents, long-term stabilization strategies, immunogenicity enhancement (e.g., adjuvants), and encapsulation options such as liposomes

Most Promising Initial Concepts

1. Frozen-State Lithography with Post-Thaw Processing  
    One of the most promising strategies may be to laser-fragment the tissue while it remains frozen under a thin layer of buffer. After processing, the sample could be refrozen and transported in that state to the clinic. Immediately prior to injection, the sample would be thawed, lightly sonicated in the presence of stabilizing reagents, and combined with adjuvants. The frozen matrix could help preserve protein structure and reduce unwanted degradation during fragmentation.
2. Matrix-Embedded Fragmentation for Implant or Reprocessing  
    A second intriguing possibility is to embed the fragmented material within a stabilizing matrix—such as a biocompatible adhesive or gel. This material could be implanted directly as a depot or further processed (e.g., fragmented again or extracted) prior to injection. This approach may offer additional control over delivery, localization, and immunological presentation.

This early-stage research could inform key design decisions for a novel class of personalized cancer vaccines. With careful optimization of optical, chemical, and physical parameters, this platform has the potential to produce stable, immunogenic antigen fragments in a controlled and reproducible way. A systematic exploration of these variables will be essential to determine the best combination for preserving native structure while maximizing immune activation.

**Works Cited**

1) Olivier T, Migliorini D. Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence? Rev Neurol (Paris). 2023 Jun;179(5):502-505. doi: 10.1016/j.neurol.2023.03.014. Epub 2023 Apr 1. PMID: 37012085.

2) Li, Yuan, et al. “Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine.” Advanced Science, 26 Mar. 2025, [https://doi.org/10.1002/advs.202502937. Accessed 7 Apr. 2025](https://doi.org/10.1002/advs.202502937.%20Accessed%207%20Apr.%202025).

3) Segal, Jeremy P, et al. “Use of Laser-Capture Microdissection for the Identification of Marker Genes for the Ventromedial Hypothalamic Nucleus.” The Journal of Neuroscience, vol. 25, no. 16, 20 Apr. 2005, pp. 4181–4188, [https://doi.org/10.1523/jneurosci.0158-05.2005. Accessed 1 Dec. 2023](https://doi.org/10.1523/jneurosci.0158-05.2005.%20Accessed%201%20Dec.%202023).

4) Yang, Muyang, et al. Exploration, vol. 4, no. 6, 28 Mar. 2024, [https://doi.org/10.1002/exp.20230171. Accessed 11 Apr. 2025](https://doi.org/10.1002/exp.20230171.%20Accessed%2011%20Apr.%202025).

5) Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine. 2015 Dec 16;33(51):7415-7422. doi: 10.1016/j.vaccine.2015.05.105. Epub 2015 Jul 3. PMID: 26148880; PMCID: PMC4684480.
